ASCEND Data Puts InterMune’s Pirfenidone On Top
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.
You may also be interested in...
Deal Watch: Roche Wins Potential Blockbuster Esbriet In $8.3B Buyout Of InterMune
While Valeant prepares for an October court date to resolve Allergan’s attempt to fend off its latest takeover attempt, the acquisitive Canadian specialty firm picked up some dermatology products from Valeo Pharma. Also this week, Cilag acquired Covagen and Vaccinogen raised $80 million for development of OncoVAX.
Roche Wins InterMune, But For A Price
With the $8.3 billion purchase price, Roche gains InterMune’s sole drug, pirfenidone for idiopathic pulmonary fibrosis, pending at FDA with action expected Nov. 23.
Two Treatments For IPF Edge Closer To Market, Will Come Down To Subtle Differences
InterMune’s pirfenidone and Boehringer Ingelheim’s nintedanib are neck-and-neck in the race to be the first drug interventions in the U.S. for the fatal lung disease. Phase III data from both drugs were presented at the American Thoracic Society meeting and published in the NEJM May 18.